[ Back to EurekAlert! ] Public release date: 23-Nov-2008
[ | E-mail Share Share ]

Contact: Angela Colmone
acolmone@asip.org
301-634-7953
American Journal of Pathology

Melatonin may save eyesight in inflammatory disease

Buenos Aires, Argentina — Current research suggests that melatonin therapy may help treat uveitis, a common inflammatory eye disease. The related report by Sande et al., "Therapeutic Effect of Melatonin in Experimental Uveitis," appears in the December issue of The American Journal of Pathology.

People with uveitis develop sudden redness and pain in their eyes, and their vision rapidly deteriorates. Untreated, uveitis can lead to permanent vision loss, accounting for an estimated 10-15% of cases of blindness in the US. Uveitis has a wide variety of causes, including eye injury, cancer, infection, and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. There is currently no optimal treatment for uveitis. Corticoid steroid eye drops are often used; however, long-term corticoid use has many negative side effects, including the possible development of glaucoma.

Researchers lead by Dr. Ruth Rosenstein of The University of Buenos Aires and The National Research Council (CONICET) hypothesized that melatonin, which regulates sleep/wake cycles and reduces jet lag, may be able to prevent the ocular inflammation in uveitis. They found in an experimental model of uveitis that levels of two factors that contribute to inflammation, TNFα and NFκB, were reduced with melatonin treatment. Importantly, melatonin treatment also decreased the appearance of clinical symptoms of uveitis such as inflammation, blood vessel expansion and cataract, and protected the blood-ocular barrier integrity.

Taken together, the data from Sande et al suggest that "melatonin, which lacks adverse collateral effects even at high doses, could be a promising resource in the management of uveitis. Alone or combined with corticosteroid therapy, the anti-inflammatory effects of melatonin may benefit patients with chronic uveitis and decrease the rate and degree of corticosteroid-induced complications." Future studies will aim at understanding the mechanisms governing melatonin protection in the eye.

###

This work was supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT), the University of Buenos Aires, CONICET, Argentina, and the John Simon Guggenheim Memorial Foundation.

Sande PH, Fernandez DC, Aldana Marcos HJ, Chianelli MS, Aisemberg J, Silberman DM, Sáenz, DA, Rosenstein RE: Therapeutic effect of melatonin in experimental uveitis. Am J Pathol 2008 173:1702-1713

For press copies of the articles, please contact Dr. Angela Colmone at 301-634-7953 or acolmone@asip.org or the Journal Editorial Office at 301-634-7959.

For more information on Dr. Rosenstein, please contact at: ruthr@fmed.uba.ar

The American Journal of Pathology, official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.